Cite

HARVARD Citation

    Ou, S. et al. (2020). Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung cancer. pp. 22-27. [Online]. 
  
Back to record